ELIZABETH BELLOMY: Open Payments
NPI 1780245837 · ROCKWALL, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,851 in 137 payments from 25 companies in 2025. Trend: 2023 $873 · 2024 $1,682 · 2025 $2,851
Food & beverage: $2,851
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $306 |
| Axsome Therapeutics, Inc. | 8 | $301 |
| GlaxoSmithKline, LLC. | 13 | $220 |
| AstraZeneca Pharmaceuticals LP | 9 | $196 |
| Astellas Pharma US Inc | 9 | $191 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $189 |
| Corcept Therapeutics | 6 | $162 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $160 |
| Kowa Pharmaceuticals America, Inc. | 7 | $139 |
| Amgen Inc. | 11 | $137 |
Products named: Auvelity, Veozah, XIFAXAN, VRAYLAR, Korlym, CAPLYTA, ZORYVE, TRELEGY ELLIPTA.
Industry payments across TX — which companies pay providers there.
